HAVCR2 and non-small cell lung carcinoma: HAVCR2 (Tim-3) has been shown to be expressed in the TME of NSCLC and affect T cell activation and can be used as a potential modulator of cancer immunotherapy to enhance the anti-tumor effect of checkpoint inhibitors [51, 52].